Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 13876 record(s)

Req # A-2020-001898

From January 1 2010 to March 25, 2021, a report for all New Drug Submissions (NDS) with the current status of “cleared” that contains the date that the submission was approved, sponsor name, and brand name of the drug.

Organization: Health Canada

78 page(s)
April 2021

Req # A-2020-000813

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03170851.

Organization: Health Canada

20 page(s)
April 2021

Req # A-2020-000879

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-106577-364, Deputy Ministerial meeting with Genome Canada.

Organization: Health Canada

4 page(s)
April 2021

Req # A-2020-001008

Adverse Drug Reaction (ADR) for DOCETAXEL. Report number: E2B_02874464.

Organization: Health Canada

11 page(s)
April 2021

Req # A-2020-001233

Adverse Drug Reaction (ADR) for Pheburane® (Sodium Phenylbutyrate). Report number: E2B_03075820.

Organization: Health Canada

11 page(s)
April 2021

Req # A-2020-001321

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-075336-232, Canadian Human Rights Commission’s Horizontal Audit on Employment of Racialized People in Executive and Management Positions in the Public…

Organization: Health Canada

53 page(s)
April 2021

Req # A-2020-001357

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-113937-85, Results of Health Canada’s application to Mediacorp’s 2021 Top 100 Employers Competition.

Organization: Health Canada

6 page(s)
April 2021

Req # A-2020-001441

Adverse Reaction Reports (AERs) for ANTI-THYMOCYTE GLOBULIN (RABBIT). Report numbers: E2B_03058764, E2B_03058773, E2B_03058779, E2B_03062549, E2B_03062567, E2B_03062578, E2B_03062587, E2B_03062592, E2B_03064020, E2B_03064028, E2B_03064032,…

Organization: Health Canada

105 page(s)
April 2021

Req # A-2020-001470

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-123456-504, 2020 Association of Professional Executives of the Public Service - Awards of Excellence.

Organization: Health Canada

14 page(s)
April 2021

Req # A-2020-001590

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03343424.

Organization: Health Canada

10 page(s)
April 2021
Date modified: